Singapore HSA accepts AffaMed’s NDA for ocular treatment

The Singapore Health Sciences Authority (HSA) has accepted the new drug application (NDA) for AffaMed Therapeutics’ DEXTENZA (0.4 mg dexamethasone…

Nicox partners with Kowa to develop eye therapy in Japan

French ophthalmology company Nicox has licensed its IOP eye drop NCX 470 to Japanese pharmaceutical Kowa Company. Kowa will gain…

Cristália signs licensing deal for Formosa’s APP13007

Cristália Produtos Químicos Farmacéuticos has signed an agreement to license exclusive rights to market Taiwanese company Formosa Pharmaceuticals’ APP13007  (clobetasol…

Sandoz to acquire Coherus’ CIMERLI ophthalmology franchise

Sandoz has entered an agreement for the acquisition of the CIMERLI ophthalmology franchise from Coherus BioSciences. This move is aimed…

Alcon’s dry eye drug achieves primary endpoints in Phase III trials

Switzerland-based Alcon’s dry eye disease drug AR-15512 achieved primary endpoints in two Phase III trials, COMET-2 and COMET-3. In light…

FDA rejects Aldeyra’s dry eye drug, asks for more clinical data

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics regarding its new…


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.